IN THE SPOTLIGHT

EZR–ROS1 rearrangement as a novel mechanism of acquired resistance to EGFR-TKIs in NSCLC: a case report and literature review

EZR–ROS1 rearrangement as a novel mechanism of acquired resistance to EGFR-TKIs in NSCLC: a case report and literature review

Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation

Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation

Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation

Targeting EGFR With Quinazoline‐4‐One/Chalcone Hybrids: Design, Synthesis, and Anticancer Evaluation

PFS 超 35 个月!奥希替尼联合化疗一线治疗 EGFR L858R 合并 TP53 共突变晚期肺癌病例分享_腾讯新闻

PFS 超 35 个月!奥希替尼联合化疗一线治疗 EGFR L858R 合并 TP53 共突变晚期肺癌病例分享_腾讯新闻

In silico evaluation of (benzo)chromeno[3,4-c]pyridine derivative as dual EGFR/HER2 inhibitors for non-small cell lung cancer

In silico evaluation of (benzo)chromeno[3,4-c]pyridine derivative as dual EGFR/HER2 inhibitors for non-small cell lung cancer

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)

A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)

Novel pyrazole–oxadiazole–chalcone/oxime hybrids as dual EGFR/VEGFR-2 inhibitors with promising anticancer potential: a comprehensive cytotoxicity evaluation, mechanistic insights and SAR analysis

Novel pyrazole–oxadiazole–chalcone/oxime hybrids as dual EGFR/VEGFR-2 inhibitors with promising anticancer potential: a comprehensive cytotoxicity evaluation, mechanistic insights and SAR analysis

Design and synthesis of novel thiazole/1,2,4-triazole/quinoline hybrids as antiproliferative agents, apoptosis inducers, immunomodulators, and multi-EGFR/BRAFV600E/HER-2 inhibitors

Design and synthesis of novel thiazole/1,2,4-triazole/quinoline hybrids as antiproliferative agents, apoptosis inducers, immunomodulators, and multi-EGFR/BRAFV600E/HER-2 inhibitors